Search alternatives:
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
20801
-
20802
Table_1_Aroma profiles of sweet cherry juice fermented by different lactic acid bacteria determined through integrated analysis of electronic nose and gas chromatography–ion mobili...
Published 2023“…A total of 50 volatile compounds characterized the aromatic profiles of the fermented juices by HS-GC–IMS. …”
-
20803
DataSheet1_Effects of pharmacogenomics-guided treatment on medication adherence and the antidepressant switching rate in major depressive disorder.docx
Published 2024“…Background<p>In the treatment of depression, medication plays a crucial role. However, insufficient patient adherence to medication often results in unsatisfactory treatment outcomes, increasing both the recurrence and rehospitalization rates of depression, and consequently imposing a greater economic burden on the healthcare system.…”
-
20804
-
20805
-
20806
-
20807
-
20808
-
20809
-
20810
-
20811
-
20812
-
20813
-
20814
Data_Sheet_1_SWL-1 Reverses Fluconazole Resistance in Candida albicans by Regulating the Glycolytic Pathway.doc
Published 2020“…In this study, we show that SWL-1 reverses resistance to fluconazole in C. albicans when delivered in combination, with a sharp decrease in the IC<sub>50</sub> of fluconazole from >200 to 3.74 ± 0.25 μg/ml, and also reverses the fluconazole resistance of C. albicans in vitro, with IC<sub>50</sub> from >200 to 5.3 ± 0.3 μg/ml. …”
-
20815
An Integrated Disease/Pharmacokinetic/Pharmacodynamic Model Suggests Improved Interleukin-21 Regimens Validated Prospectively for Mouse Solid Cancers
Published 2011“…Simulations of the verified model surfaced important therapeutic insights: (1) Fractionating the standard daily regimen (50 µg/dose) into a twice daily schedule (25 µg/dose) is advantageous, yielding a significantly lower tumor mass (45% decrease); (2) A low-dose (12 µg/day) regimen exerts a response similar to that obtained under the 50 µg/day treatment, suggestive of an equally efficacious dose with potentially reduced toxicity. …”
-
20816
-
20817
-
20818
-
20819
-
20820